David Smadja

Has grant

Professor

Université Paris-Saclay

France

Research Interests

Explore related searches

Professors in France Professors in Immunology Immunology professors in France

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor David Smadja is a faculty member at Université de Paris, France. His research areas include endothelial progenitor cells, cardiovascular regenerative medicine, and therapeutic strategies for thrombo-inflammation. He has contributed significantly to our understanding of angiogenic characteristics and polygenic risk factors related to venous thromboembolism. His recent publications highlight innovative approaches to cancer treatment and the implications of anticoagulants in clinical settings.

Recent Grants

Grant: Close

RETINAVS

Open Date:

Close Date:

Grant: Close

Les "Very small embryonic-like stem cells" comme nouvel outil de

Open Date:

Close Date:

Grant: Close

SARCODO- Flash COVID

Open Date:

Close Date:

Articles (21)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (18)

Valeria Lo Faro

University Medical Center Groningen

NETHERLANDS

David Smadja

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (21)

Targeting TXNIP in endothelial progenitors mitigates IL-8-induced neutrophil recruitment under metabolic stress

Extracellular Microvesicles vs. Mitochondria: Competing for the Top Spot in Cardiovascular Regenerative Medicine

Understanding the Angiogenic Characteristics of Clinical-Grade Mesenchymal Stromal Cells Isolated from Human Umbilical Cord

Multi-ancestry polygenic risk scores for venous thromboembolism

Acute phase determinant of post-thrombotic syndrome: A review of the literature

Développement clinique des thérapeutiques anti-facteur XII ciblant la thrombo-inflammation

<scp>DOAC‐Remove</scp> to counteract the interference of <scp>anti‐Xa</scp> oral anticoagulants on the monitoring of heparin

Hyperthermia for Targeting Cancer and Cancer Stem Cells: Insights from Novel Cellular and Clinical Approaches

Platelet Activation and Severe Bleeding During Extracorporeal Carbon Dioxide Removal in Chronic Obstructive Pulmonary Disease Patients

The Onset of Intussusceptive Angiogenesis in COVID-19 Patients Might Come from the Mobilization of Stem Cell Sub-Populations Expressing the Hemangioblast Marker CD143

Multi-ancestry polygenic risk scores for venous thromboembolism

Endoglin Is an Endothelial Housekeeper against Inflammation: Insight in ECFC-Related Permeability through LIMK/Cofilin Pathway

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Endothelial Colony-Forming Cells from Idiopathic Pulmonary Fibrosis Patients Have a High Procoagulant Potential.

A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement.

Autoregulation of Pulsatile Bioprosthetic Total Artificial Heart is Involved in Endothelial Homeostasis Preservation.

Initial bridge to transplant experience with a bioprosthetic autoregulated artificial heart.

Respiratory mechanics and gas exchanges in the early course of COVID-19 ARDS: a hypothesis-generating study.

Curative anticoagulation prevents endothelial lesion in COVID-19 patients.

Severity of endothelial dysfunction is associated with the occurrence of hemorrhagic complications in COPD patients treated by extracorporeal CO2 removal.

Collaborators (18)

Valeria Lo Faro

Aurélien Corneau

Carmelo Bernabeu

Elisa Rossi

Teunis B H Geijtenbeek

Qian Zhang

Elisa Frezza

Guillaume Goudot

Régis Bobe

Stephanie Boisson-Dupuis

Ali AMARA

Pawel Zawadzki

Pärt Peterson

Weihong Tang

Jeremy Manry

Michael Abers

Kerry Dobbs

Jingwen Gu

Make your next move.